Cost-effectiveness of duloxetine in chronic low back pain: a Quebec societal perspective


Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

PubMedID
23250234

DOI
10.1097/BRS.0b013e31828264f9

Indexing Status
Subject indexing assigned by NLM

MeSH
Age Factors; Aged; Amitriptyline /adverse effects /economics /therapeutic use; Analgesics /adverse effects /economics /therapeutic use; Cardiovascular Diseases /chemically induced; Celecoxib; Chronic Disease; Clinical Trials as Topic; Cost-Benefit Analysis; Duloxetine Hydrochloride; Gastrointestinal Diseases /chemically induced; Humans; Hydromorphone /adverse effects /economics /therapeutic use; Low Back Pain /drug therapy; Markov Chains; Middle Aged; Models, Economic; Naproxen /adverse effects /economics /therapeutic use; Ontario; Osteoarthritis /drug therapy; Outcome Assessment (Health Care) /economics /statistics & numerical data; Oxycodone /adverse effects /economics /therapeutic use; Pregabalin; Pyrazoles /adverse effects /economics /therapeutic use; Quality-Adjusted Life Years; Quebec; Sulfonamides /adverse effects /economics /therapeutic use; Thiophenes /adverse effects /economics /therapeutic use; gamma-Aminobutyric Acid /adverse effects /analogs & derivatives /economics /therapeutic use

AccessionNumber
22013026406

Date bibliographic record published
23/09/2013